This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04935359
Recruitment Status : Active, not recruiting
First Posted : June 23, 2021
Last Update Posted : February 28, 2024
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Tracking Information
First Submitted Date  ICMJE June 21, 2021
First Posted Date  ICMJE June 23, 2021
Last Update Posted Date February 28, 2024
Actual Study Start Date  ICMJE September 30, 2021
Estimated Primary Completion Date June 28, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 21, 2021)
  • Safety run-in part: Percentage of participants with dose limiting toxicities (DLTs) during the first cycle (4 weeks) of treatment. [ Time Frame: Up to 4 weeks ]
    Percentage of participants with DLTs during the first cycle of treatment in the safety run-in part. A DLT is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness or concomitant medication that occurs within the first cycle of treatment with NIS793 in combination with gemcitabine and nab-paclitaxel
  • Randomized part: Overall survival (OS) [ Time Frame: From randomization up to death, assessed up to approximately 19 months ]
    OS is defined as the time from date of randomization to date of death due to any cause.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 16, 2023)
  • Percentage of participants with Adverse Events (AEs) [ Time Frame: Up to approximately 19 months ]
    Percentage of participants with AEs including changes in laboratory parameters, vital signs, body weight and cardiac assessments
  • Percentage of participants with dose interruptions and dose reductions of NIS793 in combination with gemcitabine and nab-paclitaxel [ Time Frame: Up to approximately 19 months ]
    Tolerability measured by the percentage of participants who have dose adjustments (interruptions or reductions) of NIS793
  • Dose intensity of NIS793 in combination with gemcitabine and nab-paclitaxel [ Time Frame: Up to approximately 19 months ]
    Tolerability measured by the dose intensity of NIS793. Dose intensity will be computed as the ratio of actual cumulative dose received and actual duration of exposure
  • Progression-free survival (PFS) by investigator assessment per RECIST 1.1 [ Time Frame: From enrollment (run-in part) or randomization (randomized part) up to disease progression or death, assessed up to approximately 19 months ]
    PFS defined as the time from the date of enrollment (run-in part) or randomization (randomized part) to the date of the first documented progression based on investigator assessment and according to RECIST 1.1 or death due to any cause.
  • Overall response rate (ORR) by investigator assessment per RECIST 1.1 [ Time Frame: Up to approximately 19 months ]
    ORR is defined as the proportion of participants with best overall response (BOR) of complete response (CR) or partial response (PR), as per investigator assessment and according to RECIST 1.1
  • Disease control rate (DCR) by investigator assessment per RECIST 1.1 [ Time Frame: Up to approximately 19 months ]
    DCR is the proportion of participants with BOR of CR or PR or stable disease (SD) as per investigator assessment and according to RECIST 1.1
  • Time to response (TTR) by investigator assessment per RECIST 1.1 [ Time Frame: From enrollment (run-in part) or randomization (randomized part) up to first documented response, assessed up to approximately 19 months ]
    TTR is defined as the duration of time between the date of enrollment (run-in part) or randomization (randomized part) and the date of first documented response of either CR or PR.
  • Safety run-in part: Overall Survival (OS) [ Time Frame: From enrollment up to death, assessed up to approximately 19 months ]
    OS is defined as the time from the date of enrollment to date of death due to any cause.
  • Maximum concentration (Cmax) of NIS793 in combination with gemcitabine and nab-paclitaxel [ Time Frame: From date of first study drug intake up to approximately 19 months ]
    Blood samples will be collected for analysis of Cmax of NIS793
  • Trough Concentration (Ctrough) of NIS793 in combination with gemcitabine and nab-paclitaxel [ Time Frame: From date of first study drug intake up to approximately 19 months ]
    Blood samples will be collected for analysis of Ctrough of NIS793
  • Area under the curve from time zero to the last measurable concentration sampling time (AUClast) of NIS793 in combination with gemcitabine and nab-paclitaxel [ Time Frame: From date of first study drug intake up to approximately 19 months ]
    Blood samples will be collected for analysis of AUClast of NIS793
  • Area under the curve calculated to the end of a dosing interval (tau) at steady-state (AUCtau) of NIS793 in combination with gemcitabine and nab-paclitaxel [ Time Frame: From date of first study drug intake up to approximately 19 months ]
    Blood samples will be collected for analysis of AUCtau of NIS793
  • Time to reach maximum concentration (Tmax) of NIS793 in combination with gemcitabine and nab-paclitaxel [ Time Frame: From date of first study drug intake up to approximately 19 months ]
    Blood samples will be collected for analysis of Tmax of NIS793
  • Randomized part: NIS793 serum concentration [ Time Frame: From date of first study drug intake up to approximately 19 months ]
    Blood samples will be collected for analysis of NIS793 serum concentration
  • Randomized part: Anti-drug antibodies (ADA) against NIS793 prevalence at baseline [ Time Frame: Baseline ]
    ADA (anti-NIS793) prevalence at baseline is defined as the proportion of participants who have an ADA positive result at baseline
  • Randomized part: ADA (anti-NIS793) incidence on treatment [ Time Frame: From date of first study drug intake up to approximately 19 months ]
    ADA (anti-NIS793) incidence on treatment is defined as the proportion of participants who are treatment-induced ADA positive (post-baseline ADA positive with ADA-negative sample at baseline) and treatment-boosted ADA positive (post-baseline ADA positive with titer that is at least the fold titer change greater than the ADA-positive baseline titer)
Original Secondary Outcome Measures  ICMJE
 (submitted: June 21, 2021)
  • Percentage of participants with Adverse Events (AEs) [ Time Frame: Up to approximately 19 months ]
    Percentage of participants with AEs including changes in laboratory parameters, vital signs, body weight and cardiac assessments
  • Percentage of participants with dose interruptions and dose reductions of NIS793 in combination with gemcitabine and nab-paclitaxel [ Time Frame: Up to approximately 19 months ]
    Tolerability measured by the percentage of participants who have dose adjustments (interruptions or reductions) of NIS793
  • Dose intensity of NIS793 in combination with gemcitabine and nab-paclitaxel [ Time Frame: Up to approximately 19 months ]
    Tolerability measured by the dose intensity of NIS793. Dose intensity will be computed as the ratio of actual cumulative dose received and actual duration of exposure
  • Progression-free survival (PFS) by investigator assessment per RECIST 1.1 [ Time Frame: From enrollment (run-in part) or randomization (randomized part) up to disease progression or death, assessed up to approximately 19 months ]
    PFS defined as the time from the date of enrollment (run-in part) or randomization (randomized part) to the date of the first documented progression based on investigator assessment and according to RECIST 1.1 or death due to any cause.
  • Overall response rate (ORR) by investigator assessment per RECIST 1.1 [ Time Frame: Up to approximately 19 months ]
    ORR is defined as the proportion of participants with best overall response (BOR) of complete response (CR) or partial response (PR), as per investigator assessment and according to RECIST 1.1
  • Disease control rate (DCR) by investigator assessment per RECIST 1.1 [ Time Frame: Up to approximately 19 months ]
    DCR is the proportion of participants with BOR of CR or PR or stable disease (SD) as per investigator assessment and according to RECIST 1.1
  • Time to response (TTR) by investigator assessment per RECIST 1.1 [ Time Frame: From enrollment (run-in part) or randomization (randomized part) up to first documented response, assessed up to approximately 19 months ]
    TTR is defined as the duration of time between the date of enrollment (run-in part) or randomization (randomized part) and the date of first documented response of either CR or PR.
  • Safety run-in part: Overall Survival (OS) [ Time Frame: From enrollment up to death, assessed up to approximately 19 months ]
    OS is defined as the time from the date of enrollment to date of death due to any cause.
  • Maximum concentration (Cmax) of NIS793 in combination with gemcitabine and nab-paclitaxel [ Time Frame: From date of first study drug intake up to approximately 19 months ]
    Blood samples will be collected for analysis of Cmax of NIS793
  • Trough Concentration (Ctrough) of NIS793 in combination with gemcitabine and nab-paclitaxel [ Time Frame: From date of first study drug intake up to approximately 19 months ]
    Blood samples will be collected for analysis of Ctrough of NIS793
  • Area under the curve from time zero to the last measurable concentration sampling time (AUClast) of NIS793 in combination with gemcitabine and nab-paclitaxel [ Time Frame: From date of first study drug intake up to approximately 19 months ]
    Blood samples will be collected for analysis of AUClast of NIS793
  • Area under the curve calculated to the end of a dosing interval (tau) at steady-state (AUCtau) of NIS793 in combination with gemcitabine and nab-paclitaxel [ Time Frame: From date of first study drug intake up to approximately 19 months ]
    Blood samples will be collected for analysis of AUCtau of NIS793
  • Time to reach maximum concentration (Tmax) of NIS793 in combination with gemcitabine and nab-paclitaxel [ Time Frame: From date of first study drug intake up to approximately 19 months ]
    Blood samples will be collected for analysis of Tmax of NIS793
  • Randomized part: NIS793 serum concentration [ Time Frame: From date of first study drug intake up to approximately 19 months ]
    Blood samples will be collected for analysis of NIS793 serum concentration
  • Randomized part: Change from baseline in the patient reported outcomes measurement information system (PROMIS)-29 profile scores at week 12 [ Time Frame: Week 12 ]
    PROMIS is a commonly used self-reported measurement system of health-related quality of life and physical function. The PROMIS-29 includes 29 items that assess seven domains: physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference and pain intensity. Questions are ranked on a 5-point response scale, with higher scores at times indicating better quality of life, and at other times indicating poorer quality of life. There is a pain rating scale ranging from 0 to 10, with higher scores indicating higher pain level. Scores will be reported for each domain, as well as for pain rating.
  • Randomized part: Change from baseline in the European Quality of life questionnaire (EQ-5D-5L) scores (health index and EQ-VAS) at week 12 [ Time Frame: Week 12 ]
    The EQ-5D-5L is a 2-part questionnaire: the descriptive system and the EQ visual analogue scale (EQ-VAS). The first part assesses participant's health state in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The health state index score is calculated based on the responses to the 5 dimensions, providing a single value on a scale from -0.285 to 0.950, with higher scores indicating better health utility. The EQ-VAS records the respondent's self-rated health on a visual analogue scale with endpoints labeled 'the best health you can imagine' and 'the worst health you can imagine'. This scale is numbered from 0 to 100. 100 means the best health you can imagine.
  • Randomized part: Time-to-deterioration in domain scores in the PROMIS-29 profile [ Time Frame: From randomization up to deterioration or death, assessed up to approximately 19 months ]
    A clinically meaningful deterioration or worsening in the domain will be defined according to change from baseline scores according to minimally important differences (MID) estimates for each domain. Time-to-deterioration is defined as the time from baseline to the date of deterioration event or death due to any cause. The event of deterioration is defined as the change from baseline (worsening) of the corresponding PROMIS-29 score ≥MID, with no later change below the thereshold
  • Randomized part: Time-to-deterioration in EQ-5D-5L scores (health index and EQ-VAS) [ Time Frame: From randomization up to deterioration, assessed up to approximately 19 months ]
    The EQ-5D-5L is a 2-part questionnaire: the descriptive system and the EQ-VAS. The first part assesses participant's health state in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 5 levels. The health state index score is calculated based on the responses to the 5 dimensions, providing a single value on a scale from -0.285 to 0.950, with higher scores indicating better health. The EQ-VAS records the respondent's self-rated health on a visual analogue scale with endpoints labeled 'the best health you can imagine' and 'the worst health you can imagine'. This scale is numbered from 0 to 100. 100 means the best health you can imagine. Time-to-deterioration is defined as the time from baseline to the date of deterioration event or death due to any cause. The event of deterioration is defined as the change from baseline (worsening) in the corresponding index score ≥ 7 (EuroQol visual analogue scale) or ≥8 (health index).
  • Randomized part: Anti-drug antibodies (ADA) against NIS793 prevalence at baseline [ Time Frame: Baseline ]
    ADA (anti-NIS793) prevalence at baseline is defined as the proportion of participants who have an ADA positive result at baseline
  • Randomized part: ADA (anti-NIS793) incidence on treatment [ Time Frame: From date of first study drug intake up to approximately 19 months ]
    ADA (anti-NIS793) incidence on treatment is defined as the proportion of participants who are treatment-induced ADA positive (post-baseline ADA positive with ADA-negative sample at baseline) and treatment-boosted ADA positive (post-baseline ADA positive with titer that is at least the fold titer change greater than the ADA-positive baseline titer)
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
Official Title  ICMJE A Randomized, Double-blind, Phase III Study, Comparing NIS793 in Combination With Gemcitabine and Nab-paclitaxel Versus (vs.) Placebo Combined With Gemcitabine and Nab-paclitaxel for First Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
Brief Summary

The purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).

This study aims to explore whether blockade of Transforming Growth Factor β (TGFβ) in combination with gemcitabine/nab-paclitaxel can reduce fibrosis in PDAC, restore chemo-sensitivity and ultimately lead to improvements in overall survival (OS) and other clinically relevant outcomes.

Detailed Description

This is a randomized, double-blind, multicenter two-arm, phase III study that has two parts:

  • Safety run-in part: An open-label safety run-in part will be conducted to confirm recommended phase 3 dose (RP3D) of NIS793 in combination with gemcitabine and nab-paclitaxel. Up to approximately 10 participants will be enrolled at each dose level to achieve at least 6 evaluable participants; however, if the starting dose is not recommended and a lower dose level is tested, 10 additional participants will be enrolled. The decision to open the randomized part will be based on dose confirmation and available safety, relevant PK, and other relevant data from run-in part
  • Randomized part: Enrolled participants will be randomized to the two treatment arms.

The study treatment will be administered as a 28-day treatment cycle. Participants will be treated until unacceptable toxicity, disease progression per RECIST 1.1, withdrawal of consent or any other condition of treatment discontinuation specified in the protocol.

Note: As of 07-Jul-2023, treatment with NIS793/placebo was stopped. The trial was unblinded and study participants were allowed to continue with standard of care (SoC) chemotherapy (gemcitabine+ nab-paclitaxel) per investigator assessment.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Metastatic Pancreatic Ductal Adenocarcinoma
Intervention  ICMJE
  • Drug: NIS793
    Concentrate for solution infusion (Liquid in Vial)
  • Drug: Nab-paclitaxel
    Per locally approved formulation
  • Drug: Gemcitabine
    Per locally approved formulation
  • Drug: Placebo
    Dextrose 5% in water (D5W) solution for infusion
Study Arms  ICMJE
  • Experimental: Safety run-in part: NIS793+gemcitabine+nab-paclitaxel
    In the safety run-in part, participants will receive a combination of NIS793, gemcitabine and nab-paclitaxel.
    Interventions:
    • Drug: NIS793
    • Drug: Nab-paclitaxel
    • Drug: Gemcitabine
  • Experimental: Randomized part: NIS793+gemcitabine+nab-paclitaxel

    Participants will receive a combination of NIS793, gemcitabine and nab-paclitaxel

    Note: As of 07-Jul-2023, treatment with NIS793/placebo was stopped.

    Interventions:
    • Drug: NIS793
    • Drug: Nab-paclitaxel
    • Drug: Gemcitabine
    • Drug: Placebo
  • Placebo Comparator: Randomized part: placebo+gemcitabine+nab-paclitaxel

    Participants will receive a combination of placebo, gemcitabine and nab-paclitaxel

    Note: As of 07-Jul-2023, treatment with NIS793/placebo was stopped.

    Interventions:
    • Drug: Nab-paclitaxel
    • Drug: Gemcitabine
    • Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: August 7, 2023)
511
Original Estimated Enrollment  ICMJE
 (submitted: June 21, 2021)
490
Estimated Study Completion Date  ICMJE June 30, 2024
Estimated Primary Completion Date June 28, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Applicable for both Safety run-in and Randomized part

    • Participants aged ≥18 years with histologically or cytologically confirmed (based on local assessment and per local guidelines) mPDAC eligible for treatment in the first line setting and not amenable for potentially curative surgery
    • Presence of at least one measurable lesion assessed by Computerized Tomography (CT) and/or Magnetic Resonance Imaging (MRI) according to RECIST 1.1
    • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
    • Adequate organ function (assessed by central laboratory for eligibility)
    • Participants must have recovered from treatment-related toxicities of prior anticancer therapies to grade ≤ 1 (CTCAE v 5.0) at time of screening, except alopecia.

Main Exclusion Criteria:

  • Applicable for both Safety run-in and Randomized part

    • Previous systemic anti-cancer treatment for metastatic PDAC
    • Pancreatic neuroendocrine (islet) or acinar tumors
    • Participants with known status of microsatellite instability-high (MSI-H) or mismatch repair-deficient pancreatic cancer (if status is not already available, testing is not required at screening).
    • Participant has not recovered from a major surgery performed prior to start of study treatment or has had a major surgery within 4 weeks prior to start of study treatment.
    • Radiation therapy or brain radiotherapy ≤ 4 weeks prior to start of study treatment (palliative radiotherapy to bone lesions allowed > 2 weeks prior to start of study treatment).
    • Impaired cardiac function or clinically significant cardio-vascular disease
    • Use of hematopoietic growth factors or transfusion support ≤ 2 weeks prior to start of study treatment.
    • Participant has conditions that are considered to have a high risk of clinically significant gastrointestinal tract bleeding or any other condition associated with or history of significant bleeding.
    • Serious non-healing wounds.
    • Pregnant or breast-feeding women
    • Women of childbearing potential, unless willing to use highly effective contraception methods during treatment and after stopping study treatments as indicated
    • Pre-existing peripheral neuropathy > grade 1 (CTCAE v5.0)
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Belgium,   Brazil,   Canada,   China,   Czechia,   Finland,   France,   Germany,   Greece,   Hungary,   Israel,   Italy,   Japan,   Korea, Republic of,   Netherlands,   Norway,   Russian Federation,   Singapore,   Slovakia,   Spain,   Sweden,   Switzerland,   Taiwan,   Turkey,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04935359
Other Study ID Numbers  ICMJE CNIS793B12301
2021-000591-10 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Current Responsible Party Novartis ( Novartis Pharmaceuticals )
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Novartis Pharmaceuticals
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
PRS Account Novartis
Verification Date February 2024

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP